Diabetes drug company say efficiency is proven

Novartis, a global pharmaceutical company, have claimed that their new clinical data proves the efficacy of diabetes drug Galvus. The company are providing a new safety profile to regulators.
New data from clinical trials will be published in Diabetes, Obesity and Metabolism. The data apparently confirms the efficiency of the new oral medicine as a leading oral treatment for type 2 diabetes.
Beyond this, the company have provided a safety update to European regulators, making a further case that Galvus, when administered in the correct doses, is safe. The study data also states that Glavus is efficient alongside diabetes drug metformin. The drug was apparently well-tolerated and didn’t cause weight gain.
Novartis are in discussion with the US Food and Drug Administration on whether Galvus can be approved for US use.